Severe Combined Immunodeficiency | Market Size, Share & Growth Report 2024-2035

North America holds the regulatory approvals, the screening infrastructure and most of the clinical programmes. Newborn screening reached all 50 United States states in 2018, and the population-based incidence estimate this market relies on, approximately 1 in 65,000 births with a confidence interval of 1 in 51,000 to 1 in 90,000, comes from that screening. Revcovi was approved here on 5 October 2018. Both X-linked gene therapy programmes are run from here, one sponsored by St. Jude in newly diagnosed infants and one by the National Institutes of Health in previously transplanted patients, and the base-editing study in 18 participants was recruiting as of May 2025. The regional ranking rests on that documented regulatory and clinical concentration. No market size, share or revenue figure was identified for any region, because no company examined discloses product revenue for this indication.

Europe holds the only approved gene therapy for the condition and an unusual arrangement for supplying it. Strimvelis was approved by the European Medicines Agency in 2016 and originated at the San Raffaele-Telethon Institute for Gene Therapy. When Orchard Therapeutics closed its primary immunodeficiency department in March 2022, the therapy would have become unavailable, and the marketing authorisation instead transferred to Fondazione Telethon with European Commission approval on 17 July 2023. A positive CHMP opinion later recommended unlimited renewal ten years after first approval. Europe also contributes the RAG1 programme, licensed from Leiden University Medical Centre. The region therefore supplies both the approved gene therapy and a model for keeping orphan products available when their commercial owner withdraws.

No market size, prescribing or access figure specific to Asia Pacific was identified for this condition, and no company examined discloses regional revenue. The relevance of the region in the evidence found is that newborn screening coverage, which determines how many patients are identified before infection, varies considerably between countries and is not universal. Where screening is absent, severe combined immunodeficiency is diagnosed after presentation with infection, by which point outcomes from transplantation are substantially worse. The commercial consequence is that the treatable population in a country is set by its screening programme rather than by its birth rate, so regional demand cannot be inferred from population size alone.

No market size, prescribing rate or access study specific to Latin America was identified, and no regional programme was found among the companies or institutions examined. Neither approved product has an identified Latin American launch: Revcovi was approved in the United States and Strimvelis is authorised in the European Union. The structural observation available is that both definitive treatments, transplantation and gene therapy, require specialist centres with conditioning and cell-processing capability, so access depends on the presence of such centres rather than on drug supply. Where they are absent, the condition is managed with immunoglobulin replacement and antimicrobial prophylaxis, which is supportive rather than curative.

This region carries the highest documented incidence of the condition anywhere. Severe combined immunodeficiency is inherited recessively, so its frequency rises sharply with consanguinity, and screening of newborn dried blood spots in Saudi Arabia using T cell receptor excision circle testing combined with next generation sequencing has recorded a high incidence relative to other populations. That makes the region clinically important out of proportion to its commercial activity. No market size, revenue or access figure was identified for the region, and neither approved product is identified as launched here. The gap between where the disease is most common and where the approved therapies are available is wider in this region than in any other examined.